Last checked at 1 Dec 2017 07:05
SkinBioTherapeutics plc
Notification of first patent grant
Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.
The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company's first patent to progress to grant from within its portfolio of patents pending estate. The patent, numbered 2013246701 and entitled 'Probiotic bacteria', runs until 15 March 2033.
The patent is in active prosecution in other locations worldwide including Europe, USA and China.
Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix® patent family underpins the commercial potential worldwide.
"This is a step forward in preparing for human trials, which are scheduled for 2018."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO
| Tel: +44 (0) 161 468 2760 |
Cairn Financial Advisers LLP Tony Rawlinson / Emma Earl / Richard Nash
| Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments Ben Turner / James Pope
| Tel: +44 (0) 20 3621 4120
|
Instinctif Partners Melanie Toyne-Sewell / Deborah Bell | Tel: +44 (0) 20 7457 2020 SkinBio@instinctif.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.